Literature DB >> 22033342

Screening the interactions between HIV-1 neutralizing antibodies and model lipid surfaces.

Gregory J Hardy1, Yee Lam, Shelley M Stewart, Kara Anasti, S Munir Alam, Stefan Zauscher.   

Abstract

Our work is motivated by the observation that rare, broadly neutralizing antibodies (NAbs), 4E10 and 2F5, associate with HIV-1 lipids as part of a required first step in neutralization before binding to membrane-proximal antigens. Subsequently, induction of these types of NAbs may be limited by immunologic tolerance due to autoreactivity with host cell membranes. Despite the significance of this lipid reactivity there is little experimental evidence detailing NAb-membrane interactions. Simple and efficient screening assays are needed to select antibodies that have similar lipid reactivity as known NAbs. To this end we have developed a surface plasmon resonance (SPR) spectroscopy based assay that monitors antibody binding to thiol self-assembled monolayers (SAMs) that replicate salient lipid surface chemistries and NAb binding to lipid surfaces. Specifically, we probed the relative importance of charge and hydrophobicity on antibody-surface interactions. We found that NAb binding to hydrophobic thiol surfaces was significantly greater than that of control monoclonal antibodies (mAbs). Furthermore, we confirmed the importance of charge-mediated antibody surface interactions, originally suggested by results from mAb interactions with conventional lipid vesicle/bilayer surfaces. Our approach, using self-assembled thiol monolayers that replicate the binding behavior of NAbs on lipid surfaces, thus provides an efficient and useful tool to screen interactions of mAbs and lipid-reactive NAbs.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22033342      PMCID: PMC3718964          DOI: 10.1016/j.jim.2011.10.005

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  18 in total

1.  HIV vaccine design and the neutralizing antibody problem.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Wayne C Koff; Peter D Kwong; John P Moore; Gary J Nabel; Joseph Sodroski; Ian A Wilson; Richard T Wyatt
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

2.  Small-volume extrusion apparatus for preparation of large, unilamellar vesicles.

Authors:  R C MacDonald; R I MacDonald; B P Menco; K Takeshita; N K Subbarao; L R Hu
Journal:  Biochim Biophys Acta       Date:  1991-01-30

3.  Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1.

Authors:  R Bures; A Gaitan; T Zhu; C Graziosi; K M McGrath; J Tartaglia; P Caudrelier; R El Habib; M Klein; A Lazzarin; D M Stablein; M Deers; L Corey; M L Greenberg; D H Schwartz; D C Montefiori
Journal:  AIDS Res Hum Retroviruses       Date:  2000-12-10       Impact factor: 2.205

4.  The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.

Authors:  S Munir Alam; Mildred McAdams; David Boren; Michael Rak; Richard M Scearce; Feng Gao; Zenaido T Camacho; Daniel Gewirth; Garnett Kelsoe; Pojen Chen; Barton F Haynes
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

Review 5.  Preferred conformation and molecular packing of phosphatidylethanolamine and phosphatidylcholine.

Authors:  H Hauser; I Pascher; R H Pearson; S Sundell
Journal:  Biochim Biophys Acta       Date:  1981-06-16

6.  Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

Authors:  Barton F Haynes; Judith Fleming; E William St Clair; Herman Katinger; Gabriela Stiegler; Renate Kunert; James Robinson; Richard M Scearce; Kelly Plonk; Herman F Staats; Thomas L Ortel; Hua-Xin Liao; S Munir Alam
Journal:  Science       Date:  2005-04-28       Impact factor: 47.728

7.  Characterization of IgG monoclonal anti-cardiolipin/anti-beta2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies.

Authors:  M Zhu; T Olee; D T Le; R A Roubey; B H Hahn; V L Woods; P P Chen
Journal:  Br J Haematol       Date:  1999-04       Impact factor: 6.998

8.  Membrane protein biosensing with plasmonic nanopore arrays and pore-spanning lipid membranes.

Authors:  Hyungsoon Im; Nathan J Wittenberg; Antoine Lesuffleur; Nathan C Lindquist; Sang-Hyun Oh
Journal:  Chem Sci       Date:  2010-01-01       Impact factor: 9.825

9.  Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody.

Authors:  Silvia Sánchez-Martínez; Maier Lorizate; Katinger Hermann; Renate Kunert; Gorka Basañez; José L Nieva
Journal:  FEBS Lett       Date:  2006-04-17       Impact factor: 4.124

10.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more
  3 in total

1.  HIV-1 antibodies and vaccine antigen selectively interact with lipid domains.

Authors:  Gregory J Hardy; Gene C Wong; Rahul Nayak; Kara Anasti; Michael Hirtz; Joseph G Shapter; S Munir Alam; Stefan Zauscher
Journal:  Biochim Biophys Acta       Date:  2014-07-11

2.  Biomimetic supported lipid bilayers with high cholesterol content formed by α-helical peptide-induced vesicle fusion.

Authors:  Gregory J Hardy; Rahul Nayak; S Munir Alam; Joseph G Shapter; Frank Heinrich; Stefan Zauscher
Journal:  J Mater Chem       Date:  2012-08-28

3.  Model cell membranes: Techniques to form complex biomimetic supported lipid bilayers via vesicle fusion.

Authors:  Gregory J Hardy; Rahul Nayak; Stefan Zauscher
Journal:  Curr Opin Colloid Interface Sci       Date:  2013-10-01       Impact factor: 6.448

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.